Investigators examined the effect of testosterone replacement therapy on metabolic syndrome and vascular function in obese males with hypogonadism.
At 12 years of testosterone treatment, HbA1c decreased to 5.5±0.3%.
After 1 year of therapy, men who underwent testosterone therapy experienced improvement in bone mineral density and mood.
A 28-year-old male patient, otherwise in good health, presented with acute onset vertigo, nausea, and vomiting resulting from exogenous testosterone use.
Testosterone has been identified as a "potent inhibitor" of lymphoid cells responsible for producing proteins that lead to lung inflammation.
Endocrinology Advisor Articles
- Predictors of Success for Insulin-to-Liraglutide Switch for Type 2 Diabetes
- Efficacy and Safety of Alirocumab in Diabetes Mellitus
- Safety of DPP-IV Inhibitor, Cardiovascular Events After ACS in Type 2 Diabetes
- Transgender Youth Not Willing to Delay Hormone Therapy for Fertility Preservation
- Pre-Pregnancy Programs May Improve Outcomes in Women With Type 2 Diabetes
- Diabetes Treatments
- Metformin May Decrease Colorectal Cancer Risk Among Males With Diabetes
- SGLT2 Inhibitor, GLP-1 Receptor Agonist Combination Treatment for Type 2 Diabetes: Expert Insights
- Semaglutide May Induce Weight Loss in Type 2 Diabetes Despite BMI
- FDA Clears Omnipod DASH System for Diabetes Management
- IV Fluid Infusion Rates Do Not Affect Pediatric DKA Neurologic Outcomes
- Effect of Fructose, Allulose on Postprandial Glucose Regulation in Type 2 Diabetes
- Psychiatric Morbidity Decreased After Assisted Reproductive Technology Treatment
- Fenofibrate Improves Cholesterol Levels in Type 2 Diabetes
- Sex Hormone Levels May Affect Postmenopausal Heart Disease Risk